Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R -/-) mice

Thrombosis and Haemostasis

Volumn 107, Issue 3, 2012, Pages 552-561

  Potì, Francesco ^a   Bot, Martine ^b   Costa, Sara ^a   Bergonzini, Valeria ^a   Maines, Lynn ^c   Varga, Georg ^d   Freise, Hendrik ^e   Robenek, Horst ^d   Simoni, Manuela ^a   Nofer, Jerzy Roch ^a,e  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b LEIDEN UNIVERSITY   (Netherlands)

^c APOGEE BIOTECHNOLOGY CORPORATION   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Animal models of atherosclerosis; Endothelium; High density lipoproteins; Inflammation; Sphingosine 1 phosphate

Indexed keywords

[3 (4 CHLOROPHENYL) ADAMANTANE 1 CARBOXYLIC ACID(PYRIDIN 4 YLMETHYL)AMIDE]; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P70; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENDRITIC CELL; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; HISTOLOGY; IMMUNOPHENOTYPING; LEUKOCYTE ADHERENCE; LEUKOCYTE DIFFERENTIAL COUNT; MACROPHAGE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ADAMANTANE; ANIMALS; ATHEROSCLEROSIS; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; INFLAMMATION MEDIATORS; MICE; MICE, KNOCKOUT; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPROTEIN CONVERTASES; PYRIDINES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES;

EID: 84857753699     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-08-0583     Document Type: Article

References (50)

1. Strub GM, Maceyka M, Hait NC, et al. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010; 688: 141-155.
2. Zhang B, Tomura H, Kuwabara A, et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 2005; 178: 199-205.
3. Alemany R, van Koppen CJ, Danneberg K, et al. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 2007; 374: 413-428.
4. Takabe K, Paugh SW, Milstien S, et al. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60: 181-195.
5. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, et al. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009; 78: 743-768.
6. Lucke S, Levkau B. Endothelial functions of sphingosine-1-phosphate. Cell Physiol Biochem 2010; 26: 87-96.
7. Igarashi J, Michel T. Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc Res 2009; 82: 212-220.
8. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127-159.
9. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008; 8: 753-763.
10. Weigert A, Weis N, Brüne B. Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology 2009; 214: 748-760.
11. Xia P, Gamble JR, Rye KA, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 1998; 95: 14196-14201.
12. Zhi L, Leung BP, Melendez AJ. Sphingosine kinase 1 regulates pro-inflammatory responses triggered by TNFalpha in primary human monocytes. J Cell Physiol 2006; 208: 109-115.
13. Sattler KJ, Elbasan S, Keul P, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010; 105: 821-832.
14. Argraves KM, Sethi AA, Gazzolo PJ, et al. S1P, dihydro-S1P and C24: 1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis 2011; 10: 70.
15. Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 2007; 48: 2325-2333.
16. Nofer JR. High-density lipoprotein, sphingosine 1-phosphate, and atherosclerosis. J Clin Lipidol 2008; 2: 4-11.
17. Rodríguez C, González-Díez M, Badimon L, et al. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009; 101: 665-673.
18. González-Díez M, Rodríguez C, Badimon L, et al. Prostacyclin induction by highdensity lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost 2008; 100: 119-126.
19. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115: 501-508.
20. Keul P, Tölle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 607-613.
21. French KJ, Zhuang Y, Maines LW, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010; 333: 129-139.
22. Maines LW, Fitzpatrick LR, French KJ, et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008; 53: 997-1012.
23. Yusof M, Kamada K, Gaskin FS, et al. Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide. Am J Physiol Heart Circ Physiol 2007; 292: H3032-H3037.
24. Nofer JR, van der Giet M, Tölle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113: 569-581.
25. Varga G, Balkow S, Wild MK, et al. Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood 2007; 109: 661-669.
26. Maines LW, French KJ, Wolpert EB, et al. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci 2006; 47: 5022-5031.
27. Miyamoto T, Matsumori A, Hwang MW, et al. Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol 2001; 37: 1713-1718.
28. Peng X, Hassoun PM, Sammani S, et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004; 169: 1245-1251.
29. Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004; 153: 108-121.
30. Fujii R, Kanai T, Nemoto Y, et al. FTY720 suppresses CD4+CD44highCD62L-effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 2006; 291: G267-G274.
31. Kharel Y, Lee S, Snyder AH, et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 2005; 280: 36865-36872.
32. Jun DJ, Lee JH, Choi BH, et al. Sphingosine-1-phosphate modulates both lipolysis and leptin production in differentiated rat white adipocytes. Endocrinology 2006; 147: 5835-5844.
33. Chi H, Flavell RA. Cutting edge: regulation of T cell trafficking and primary immune responses by sphingosine 1-phosphate receptor 1. J Immunol 2005; 174: 2485-2488.
34. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
35. Allende ML, Dreier JL, Mandala S, et al. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 2004; 279: 15396-15401.
36. Alfonso C, McHeyzer-Williams MG, Rosen H. CD69 down-modulation and inhibition of thymic egress by short-and long-term selective chemical agonism of sphingosine 1-phosphate receptors. Eur J Immunol 2006; 36: 149-159.
37. Jin Y, Knudsen E, Wang L, et al. Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood 2003; 101: 4909-4915.
38. Dorsam G, Graeler MH, Seroogy C, et al. Transduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell functions by the S1P1 G proteincoupled receptor. J Immunol 2003; 171: 3500-3507.
39. Gräler MH, Huang MC, Watson S, et al. Immunological effects of transgenic constitutive expression of the type 1 sphingosine 1-phosphate receptor by mouse lymphocytes. J Immunol 2005; 174: 1997-2003.
40. Müller H, Hofer S, Kaneider N, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 2005; 35: 533-545.
41. Gollmann G, Neuwirt H, Tripp CH, et al. Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. Int Immunol 2008; 20: 911-923.
42. Lan YY, Tokita D, Wang Z, et al. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival. Transpl Immunol 2008; 20: 88-94.
43. Schröder M, Richter C, Juan MH, et al. The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen. Mol Immunol 2011; 48: 1139-1148.
44. Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 2008; 103: 1220-1231.
45. Ait-Oufella H, Taleb S, Mallat Z, et al. Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol 2009; 31: 23-33.
46. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25-32.
47. Wang L, Xing XP, Holmes A, et al. Activation of the sphingosine kinase-signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circ Res 2005; 97: 891-899.
48. Limaye V, Xia P, Hahn C, et al. Chronic increases in sphingosine kinase-1 activity induce a pro-inflammatory, pro-angiogenic phenotype in endothelial cells. Cell Mol Biol Lett 2009; 14: 424-441.
49. Tamama K, Okajima F. Sphingosine 1-phosphate signaling in atherosclerosis and vascular biology. Curr Opin Lipidol 2002; 13: 489-495.
50. Okajima F, Sato K, Kimura T. Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I. Endocr J 2009; 56: 317-334.